What's new in Gene2Rx 4.6

If you have the BAM or CRAM file behind your whole genome VCF, Gene2Rx can now measure CYP2D6 deletions, duplications and gene fusions from your sequencing reads, which a VCF alone can't show. Your browser sends only the small sections of the file the analysis needs, and checks before you pay that there's enough data. How it works.

Star allele definitions now follow PharmVar 6.2.29 and CPIC's current allele function tables. SLCO1B1 results use the updated allele names, so some names differ from earlier reports. Allele calling is also improved for some whole genome VCFs and consumer DNA files.

Your report now opens as a page you can search by medication, brand name or drug class. Every medication and drug class has its own page with your result for each gene in plain language, and a gene overview shows what stands out and how common each of your results is. Download a short PDF with every result in plain language, or a detailed PDF with the full guideline recommendations for your doctor or pharmacist. See the example report.

Many prescriptions combine two or more drugs in one pill. The report now covers combination products such as Norco, Tylenol with Codeine, Ultracet and Caduet, each with the guidance for the ingredients your genes affect. How combination products are handled. Version 4.5 also adds hydrocodone, with CPIC guidance based on CYP2D6, and risperidone, with Dutch Pharmacogenetics Working Group (DPWG) guidance based on CYP2D6. Aripiprazole, brexpiprazole, clozapine and pimozide now show the DPWG recommendation next to the FDA one.

We rewrote the plain-language explanations throughout the report. Medications that depend on a gene we could not determine from your data now say "Unable to determine".

For WGS customers, v4 checks selected variants in RYR1 and CACNA1S linked to malignant hyperthermia, a serious reaction to certain anesthesia medications. This assessment covers six inhaled anesthetics and succinylcholine. A result with no listed variant detected does not rule out susceptibility. The separate BCHE assessment for succinylcholine remains available for both array and WGS customers. Read the anesthesia overview.

Following updated guidance from the Clinical Pharmacogenetics Implementation Consortium (CPIC), v4 considers your TPMT and NUDT15 results together for azathioprine, mercaptopurine, and thioguanine. If a combined result cannot be determined, your report still shows any available guidance from each gene.

• Hydralazine and NAT2: acetylator status and drug exposure.
• Topical minoxidil and SULT1A1: information about how your genetics may affect treatment response, included for array and WGS customers when the relevant genetic variant can be determined directly or through imputation.

Finasteride and dutasteride have educational pages but are not assessed in the report.

V4 also supports combined interpretations for selected antidepressants, statins, warfarin, and incretin-related findings. Saved interpretations and activity scores keep report results consistent across connected tools. Drug-specific evidence limitations remain part of the interpretation.

Existing reports retain their original assessments. Report updates follow the existing purchase and subscription rules. See the version history or review Full Report coverage.